Exagen (XGN) Gains from Investment Securities (2018 - 2026)

Exagen has reported Gains from Investment Securities for 9 years, with the latest figure at $100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 762.27% YoY), and the FY2025 full-year result was -$792000.0, down 104.65% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $100000.0, up from -$645000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $2.7 million in Q3 2025, with the low at -$645000.0 in Q4 2025.
• Historically, Gains from Investment Securities has averaged $278000.0 across 5 years, with a median of $100000.0 in 2026.
• The largest YoY upside for Gains from Investment Securities was 1346.15% in 2022 against a maximum downside of 231.82% in 2022.
• Exagen's Gains from Investment Securities stood at $641000.0 in 2022, then fell by 9.98% to $577000.0 in 2023, then sank by 167.07% to -$387000.0 in 2024, then slumped by 66.67% to -$645000.0 in 2025, then jumped by 115.5% to $100000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $100000.0 (Q1 2026), -$645000.0 (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.